27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
- Rocket Pharmaceuticals Inc (NASDAQ:RCKT) has agreed to acquire Renovacor Inc (NYSE:RCOR) in an all-stock transaction for an implied value of approximately $2.60 per share.
- The transaction is currently expected to close by the first quarter of 2023.
- "The acquisition of Renovacor aligns with our strategy to expand our leadership position in AAV-based gene therapy for cardiac disease and gives us a perfect opportunity to continue on our mission to transform the lives of heart failure patients through the power of gene therapy," said Gaurav Shah, CEO of Rocket.
- Renovacor's most advanced program, REN-001, is an AAV-based gene therapy targeting BAG3-associated dilated cardiomyopathy (DCM), a severe form of heart failure. IND submission is planned for 2H of 2022.
- Renovacor shareholders will receive approximately 0.1676 shares of Rocket.
- The exchange ratio implies an equity deal value of approximately $53 million based on fully diluted shares outstanding, or $2.60 per share of Renovacor.
- Price Action: RCOR shares are up 14.2% at $2.17 on the last check Tuesday. RCKT shares are down 3.31% at $13.51.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!